ConductScience.org, home

Comparison · NCT02173379-2b9ea00b

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR). Trial comparisons, record NCT02173379-2b9ea00b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02173379-2b9ea00b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01090.006520.0182wilson
Risk in group 20.01080.006470.0181wilson
Risk difference, group 1 minus group 20.0000761-0.008430.00861newcombe hybrid score
Risk ratio, group 1 over group 21.010.4822.1log
Odds ratio, group 1 over group 21.010.4782.12log
Number needed to treat, for one more participant with the outcome on Absorb BVS than on XIENCE13,100from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Absorb BVSSubjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System141,282OG000
Group 2XIENCESubjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)141,291OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Target Vessel Revascularization (TVR)
Description
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR.~-TVR includes all TVR, excluding TLR
Time frame
180 days
Population
ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.

Source ClinicalTrials.gov

Trial

Title
Absorb IV Randomized Controlled Trial
NCT number
NCT02173379
Phases
NA
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Lead sponsor
Abbott Medical Devices
Results first posted
2018-07-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02173379-2b9ea00b